AR014974A1 - Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamento - Google Patents
Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamentoInfo
- Publication number
- AR014974A1 AR014974A1 ARP990101516A ARP990101516A AR014974A1 AR 014974 A1 AR014974 A1 AR 014974A1 AR P990101516 A ARP990101516 A AR P990101516A AR P990101516 A ARP990101516 A AR P990101516A AR 014974 A1 AR014974 A1 AR 014974A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr3r4
- aryl
- halo
- branched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto con actividad sobre receptores muscarínicos, que comprenden la formula (I) en donde: X1, X2, X3, X4 y X5 se seleccionan entre C, N y O; k es 0o 1; t es 0, 1 o 2; R1 es alquilo C1-8 de cadena ramificada o recta, alquenilo C2-8, alquiniloC1-8, alquilideno C1-8, alcoxi C1-8, heteroalquilo C1-8,aminoalquilo C1-8, haloalquilo C1-8, alcoxicarbonilo C1-8, hidroxialcoxi C1-8, hidroxialquilo C1-8, -SH, alquiltio C1-8, -O-CH2-C5-6 arilo, -C(O)-C5-6 arilosustituido con alquilo C1-3 o halo; arilo C5-6 o cicloalquilo C5-6 que opcionalmente comprende 1 o más heteroátomos seleccionados entre N, S y O; -C(O)NR3R4,-NR3R4, -NR3C(O)NR4R5, -CNR3R4, -OC(O)R3, -(O)(CH2)sNR3R4 o -(CH2)sNR3R4; donde R3, R4 y R5 son iguales o diferentes; cada uno es independientementeseleccionado entre H, alquilo C1-6; arilo C5-6 que opcionalmente comprende 1 o más heteroátomos seleccionados entre N, O y S, y opcionalmente sustituido conhalo o alquilo C1-6; cicloalquilo C3-6; o R3 y R4 junto con el átomo N, cuando está presente, forman una estructura de anillo cíclico que comprende 5-6 átomosseleccionados entre C, N, S y O; y s es un entero de 0 a 8; A es arilo C5-12 o cicloalquilo C5-7; cada uno comprende opcionalmente 1 o más heteroátomosseleccionados entre N, S y O; R2 es H, amino, hidroxilo, halo, o alquilo C1-6 de cadena ramificada o recta, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6,heteroalquilo C1-6, aminoalquilo C1-6, haloalquilo C1-6, alquiltio C1-6, alcoxicarbonilo C1-6, -CN, -CF3, -OR3, -COR3, NO2, -NHR3, -NHC(O)R3, -C(O)NR3R4,-NR3R4, -NR3C(O)NR4R5, -OC(O)R3, -C(O)R3R4, -O(CH2)qNR3, -CNR3R4 o -(CH2)qNR3R4; donde q es un entero desde 1 a 6; n es 0, 1, 2, 3, o 4, los grupos R2, cuandon > 1, son iguales o diferentes; p es 0 o un entero de1 a 5; Y es O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, NR7 o -CH=N-, y R7 es H o alquilo C1-4; oausente; Z es CR8R9 en donde R8 y R9 se seleccionan independientemente entre H y alquilo C1-8 recto o de cadena ramificada; siempre que cuando -(CH2)p-Y- es-(CH2)3-C(O)- o -(CH2)3-S-, y X1 a X5 son C; que -A-(R2)n y R1 no están juntos: o-metil-fenilo y n-butilo, respectivamente; fenilo y n-butilo, respectivamente;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/933,177 US20080108618A1 (en) | 1998-03-31 | 2007-10-31 | Compounds with activity on muscarinic receptors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8013398P | 1998-03-31 | 1998-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR014974A1 true AR014974A1 (es) | 2001-04-11 |
Family
ID=22155464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101516A AR014974A1 (es) | 1998-03-31 | 1999-04-05 | Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamento |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1068185A1 (es) |
JP (1) | JP2002509918A (es) |
KR (2) | KR100672186B1 (es) |
CN (1) | CN1303376A (es) |
AR (1) | AR014974A1 (es) |
AU (1) | AU762726B2 (es) |
BR (1) | BR9909277A (es) |
CA (1) | CA2326804C (es) |
MX (1) | MXPA00009569A (es) |
NO (1) | NO319835B1 (es) |
NZ (2) | NZ507204A (es) |
RU (2) | RU2230740C2 (es) |
WO (1) | WO1999050247A1 (es) |
ZA (1) | ZA200005149B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
WO2003057672A2 (en) * | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
MXPA03000145A (es) | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
JP2006502180A (ja) | 2002-09-20 | 2006-01-19 | ファイザー株式会社 | 5−ht4レセプターモジュレーターとしてのn−置換されたピペリジニル−イミダゾピリジン化合物 |
HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
WO2005016276A2 (en) * | 2003-08-05 | 2005-02-24 | Samaritan Pharmaceuticals Inc. | Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
JP4795022B2 (ja) | 2003-09-30 | 2011-10-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環化合物を含有する新規な抗真菌剤 |
KR100943555B1 (ko) | 2004-04-30 | 2010-02-22 | 워너-램버트 캄파니 엘엘씨 | 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물 |
AU2005254800B2 (en) | 2004-06-15 | 2010-12-09 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
JP5507049B2 (ja) | 2004-12-30 | 2014-05-28 | アステックス、セラピューティックス、リミテッド | 医薬品 |
AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006282403B2 (en) | 2005-08-26 | 2011-07-07 | Institute Of Medicinal Molecular Design, Inc. | Derivative having PPAR agonistic activity |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
DK2317852T3 (en) | 2008-07-16 | 2015-03-23 | Richter Gedeon Nyrt | PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands |
HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
CN102558026A (zh) * | 2011-12-27 | 2012-07-11 | 盛世泰科生物医药技术(苏州)有限公司 | 关于4-n-丁基-1-[4-(2-甲基苯基)-4-酮-1-丁基]哌啶的合成及工艺优化 |
WO2014031162A1 (en) | 2012-08-20 | 2014-02-27 | Forest Laboratories Holdings Limited | Crystalline form of carbamoyl-cyclohexane derivatives |
CN102997438A (zh) * | 2012-10-16 | 2013-03-27 | 李誊 | 改善热量利用率的电热水器控制方法 |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
MX2016008131A (es) | 2013-12-20 | 2016-09-16 | Astex Therapeutics Ltd | Compuestos heterociclos biciclicos y sus usos en terapia. |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
ES2919779T3 (es) | 2017-06-20 | 2022-07-28 | Imbria Pharmaceuticals Inc | Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2695295A (en) * | 1952-12-19 | 1954-11-23 | Mcneilab Inc | Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds |
GB874206A (en) * | 1956-09-05 | 1961-08-02 | Knoll Ag | Basic derivatives of salicylamide |
BE610830A (es) * | 1960-12-01 | |||
FR1382425A (fr) * | 1963-01-14 | 1964-12-18 | Ciba Geigy | Procédé de préparation de diaza-cyclo-alcanes, entre autres de la 3-méthyl-4-phényl-1-(2-phénylmercapto-éthyl)-pipérazine |
GB1053301A (es) * | 1963-01-14 | |||
US3488352A (en) * | 1966-10-11 | 1970-01-06 | Shulton Inc | Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof |
FR1543944A (fr) * | 1967-03-10 | 1968-10-31 | Bruneau & Cie Lab | Dérivés amidés de l'acide salicylique et leur préparation |
BE792187A (fr) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | Nouveaux derives d'alkylamines |
DE2335432A1 (de) * | 1973-07-12 | 1975-01-30 | Boehringer Mannheim Gmbh | 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung |
GB1459506A (en) * | 1974-02-18 | 1976-12-22 | Wyeth John & Brother Ltd | Piperidine derivatives |
GB1498884A (en) * | 1975-04-15 | 1978-01-25 | Wyeth John & Brother Ltd | Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
BR9711061A (pt) * | 1996-08-15 | 1999-08-17 | Schering Corp | Antagonistas muscarinicos de eter |
-
1999
- 1999-03-31 WO PCT/US1999/007057 patent/WO1999050247A1/en active IP Right Grant
- 1999-03-31 NZ NZ507204A patent/NZ507204A/en unknown
- 1999-03-31 AU AU32187/99A patent/AU762726B2/en not_active Ceased
- 1999-03-31 MX MXPA00009569A patent/MXPA00009569A/es active IP Right Grant
- 1999-03-31 CN CN99806618A patent/CN1303376A/zh active Pending
- 1999-03-31 EP EP99914306A patent/EP1068185A1/en not_active Withdrawn
- 1999-03-31 RU RU2000127105/04A patent/RU2230740C2/ru active
- 1999-03-31 JP JP2000541152A patent/JP2002509918A/ja not_active Withdrawn
- 1999-03-31 KR KR1020007010780A patent/KR100672186B1/ko not_active IP Right Cessation
- 1999-03-31 NZ NZ525108A patent/NZ525108A/en unknown
- 1999-03-31 BR BR9909277-8A patent/BR9909277A/pt not_active Application Discontinuation
- 1999-03-31 KR KR1020067023572A patent/KR20060120715A/ko not_active Application Discontinuation
- 1999-03-31 CA CA002326804A patent/CA2326804C/en not_active Expired - Fee Related
- 1999-04-05 AR ARP990101516A patent/AR014974A1/es not_active Application Discontinuation
-
2000
- 2000-09-26 ZA ZA200005149A patent/ZA200005149B/en unknown
- 2000-09-29 NO NO20004912A patent/NO319835B1/no unknown
-
2004
- 2004-03-11 RU RU2004107218/04A patent/RU2278111C2/ru active
Also Published As
Publication number | Publication date |
---|---|
NO20004912L (no) | 2000-11-23 |
MXPA00009569A (es) | 2002-08-06 |
CA2326804A1 (en) | 1999-10-07 |
RU2278111C2 (ru) | 2006-06-20 |
JP2002509918A (ja) | 2002-04-02 |
ZA200005149B (en) | 2002-01-08 |
AU762726B2 (en) | 2003-07-03 |
RU2230740C2 (ru) | 2004-06-20 |
NZ525108A (en) | 2005-02-25 |
CA2326804C (en) | 2006-05-02 |
BR9909277A (pt) | 2001-10-16 |
NO319835B1 (no) | 2005-09-19 |
KR100672186B1 (ko) | 2007-01-19 |
NO20004912D0 (no) | 2000-09-29 |
CN1303376A (zh) | 2001-07-11 |
EP1068185A1 (en) | 2001-01-17 |
WO1999050247A1 (en) | 1999-10-07 |
RU2004107218A (ru) | 2005-08-20 |
KR20010042248A (ko) | 2001-05-25 |
AU3218799A (en) | 1999-10-18 |
NZ507204A (en) | 2003-12-19 |
KR20060120715A (ko) | 2006-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR014974A1 (es) | Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamento | |
ES2604947T3 (es) | Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso | |
BRPI0110955B8 (pt) | derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. | |
AR011229A1 (es) | Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina. | |
AR017457A1 (es) | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. | |
RS51574B (sr) | JEDINJENJA PIROLO (2,3-d) PIRIMIDINA | |
DE69011628D1 (de) | 1,2-Benzisoxazolderivate, Verfahren zu deren Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen. | |
DE69127556D1 (de) | Antiatherosklerotische arylverbindungen | |
ES2084129T3 (es) | Nuevas calconas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
MX9100675A (es) | 2-amino-1,2,3,4-tetrahidronaftalenos,3-aminocromanos y 3-aminotiocromanos substituidos en el anillo,procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
PT790248E (pt) | Derivados de 3-aza-piperidona-(tetra-hidropirimidin-2-ona) e 3-oxa-piperidona(1,3 oxazin-2-ona) sua preparacao e uso como antagonistas de taquicinina/neurocinina | |
ES543421A0 (es) | Un procedimiento para preparar 1,3,4,5-tetrahidro-benz(cd) indolaminas oxigenadas en posicion 6 | |
ES2046671T3 (es) | Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas. | |
BR0111240A (pt) | Misturas estabilizadoras | |
ES2119106T3 (es) | Nuevos benzo-espiro-alquenos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
ES2063117T3 (es) | Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ATE103921T1 (de) | 1-oxa-2-oxo-8-azaspiro(4,5>decan-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen daraus. | |
AR036351A1 (es) | Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas | |
AR016501A1 (es) | Compuestos inhibidores de las fkbp, composiciones farmaceuticas, uso para la preparacion de medicamentos y procesos de preparacion e intermediarios. | |
AR037976A1 (es) | Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, una composicion farmaceutica, un producto combinado con un agente antirretroviral y el uso de las mismas para la fabricacion de un medicamento. | |
ES2058275T3 (es) | Derivados biciclicos de sulfonamida y su preparacion, su uso y formulaciones que los contienen. | |
SE8604349L (sv) | Dikloranilinderivat | |
PT1095940E (pt) | Contem derivados de 9-(3,5-dimetoxifenil)-5,8,8a,9-tetra-hidrofuro[3',4':6,7]nafto[2,3-d][1,3]dioxol-6(5ah)-ona,processo para a sua preparacao e as composicoes farmaceuticas que os | |
MX9405111A (es) | Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina). | |
ES8105319A1 (es) | Procedimiento de preparacion de derivados pirazolo (1,5-c) quinazolinos y de sus sales de adicion acidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |